Mingyue Xu

InstitutionWuhan institute of Virology
AddressWuhan
Hubei
China
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 5 Covid-19 publications, with a maximum of 1 publications in February 2020 and March 2020 and May 2020 and August 2020 and Spetember 2020
    All Publications
    Bar chart showing 23 publications over 6 distinct years, with a maximum of 5 publications in 2018 and 2020
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zhang L, Liu J, Cao R, Xu M, Wu Y, Shang W, Wang X, Zhang H, Jiang X, Sun Y, Hu H, Li Y, Zou G, Zhang M, Zhao L, Li W, Guo X, Zhuang X, Yang XL, Shi ZL, Deng F, Hu Z, Xiao G, Wang M, Zhong W. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. Virol Sin. 2020 Dec; 35(6):776-784. PMID: 32910347.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    2. Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, Zhang H, Yan Y, Zhao L, Li W, Zhang T, Xiao D, Guo X, Li Y, Yang J, Hu Z, Wang M, Zhong W. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro. ACS Infect Dis. 2020 09 11; 6(9):2524-2531. PMID: 32786284.
      Citations: 37     Fields:    Translation:AnimalsCellsPHPublic Health
    3. Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, Yang X, Shi Z, Deng F, Hu Z, Zhong W, Wang M. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020; 6:28. PMID: 32373347.
      Citations: 95     
    4. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6:16. PMID: 32194981.
      Citations: 778     
    5. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 03; 30(3):269-271. PMID: 32020029.
      Citations: 2312     Fields:    Translation:HumansAnimalsCells